No Data
No Data
OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics
Revolutionizing Stroke Treatment: The Ottawa Hospital First To Adopt Vena Medical's Innovative Device
The Healthcare Businesswomen's Association Announces Inaugural Pitch Competition for Women Innovators With Cash Prizes Up to $100K
2023 Annual Report (updated version)
OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases
Heyuan Biotech (688238.SH): The first phase of the employee stock ownership plan completed the stock purchase
Gelonghui, May 30丨Heyuan Biotech (688238.SH) announced that as of May 30, 2024, the first phase of the employee stock ownership plan had completed the purchase of the company's shares. A total of 5,508,413 shares were purchased through secondary market purchases, accounting for 0.8508% of the company's current total share capital. The average transaction price was 5.6261 yuan/share, and the total transaction amount was 30,990,802.88 yuan. The above shares will be locked in accordance with the relevant regulations of this employee stock ownership plan. The lockdown period is 12 months, that is, from May 31, 2024 to May 30, 2025
No Data